G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina, focused on discovering, developing, and delivering innovative small-molecule oncology therapies that improve outcomes for people living with cancer. The company’s flagship commercial product, COSELA® (trilaciclib), is designed to proactively protect bone marrow from the harmful effects of chemotherapy, helping patients better tolerate treatment. In addition to its marketed therapy, G1 has advanced a clinical pipeline of next-generation oncology candidates targeting unmet needs across multiple cancer types.

IPO in May 2017 (NASDAQ: GTHX) Acquired by Pharmacosmos in 2024

VISIT WEBSITE